Adipotide (also known as FTPP or CKGGRAKDC-GG-D(KLAKLAK)2) is an experimental peptidomimetic that represents a radical departure from traditional weight-loss medications. While most drugs target the brain to suppress appetite, Adipotide targets the blood supply of fat cells directly.

Below is the reported data on its benefits, mechanism, and current research status as of early 2026.

1. Primary Reported Benefits

Based on preclinical data (primate and rodent studies) and early-phase human observations, the following benefits have been reported:

• Rapid Weight Reduction: In primate studies, obese rhesus monkeys lost an average of 11% of their body weight in just 28 days.
• Targeted Fat Loss: Unlike calorie restriction, which can cause muscle loss, Adipotide specifically targets White Adipose Tissue (WAT). Imaging (DEXA and MRI) confirmed a significant reduction in visceral and subcutaneous fat volume.
• Improved Insulin Sensitivity: Research showed a 60% reduction in insulin requirements in treated subjects, suggesting a potent secondary benefit for Type 2 Diabetes and metabolic syndrome.
• Reduced Abdominal Circumference: Primate trials showed a visible reduction in “waistline” metrics, correlating with the destruction of abdominal fat depots.
• No Appetite Suppression Required: The weight loss occurs regardless of food intake behavior because the mechanism is metabolic/structural rather than neurological.

2. Mechanism of Action: “Vascular Targeting”

Adipotide works through a two-step “seek and destroy” process:

• Homing: The peptide contains a targeting sequence (CKGGRAKDC) that binds to a specific receptor (Prohibitin) found primarily on the surfaces of blood vessels supplying white fat.
• Apoptosis (Cell Death): Once bound, the “payload” part of the molecule (KLAKLAK) enters the cells and triggers programmed cell death.
• Absorption: Without a blood supply, the fat cells die and are naturally reabsorbed and metabolized by the body.

3. Comparative Data

In the current landscape of 2026, Adipotide is often compared to GLP-1 agonists (like Semaglutide or Tirzepatide).

Feature	Adipotide (Experimental)	GLP-1 Agonists (Approved)
Primary Target	Blood vessels of fat tissue	Brain (Appetite/Satiety)
Fat Type	Specifically White Adipose Tissue	General weight loss (Fat + some Lean)
Speed	Extremely rapid (weeks)	Gradual (months)
Persistence	Potential for permanent cell removal	Often requires maintenance dosing
Status	Investigational / Research only	FDA Approved / Widely available